PT  - JOURNAL ARTICLE
AU  - Jan M. Brauner
AU  - Sören Mindermann
AU  - Mrinank Sharma
AU  - Anna B. Stephenson
AU  - Tomáš Gavenčiak
AU  - David Johnston
AU  - John Salvatier
AU  - Gavin Leech
AU  - Tamay Besiroglu
AU  - George Altman
AU  - Hong Ge
AU  - Vladimir Mikulik
AU  - Meghan Hartwick
AU  - Yee Whye Teh
AU  - Leonid Chindelevitch
AU  - Yarin Gal
AU  - Jan Kulveit
TI  - The effectiveness and perceived burden of nonpharmaceutical interventions against COVID-19 transmission: a modelling study with 41 countries
AID  - 10.1101/2020.05.28.20116129
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.28.20116129
4099  - http://medrxiv.org/content/early/2020/05/29/2020.05.28.20116129.short
4100  - http://medrxiv.org/content/early/2020/05/29/2020.05.28.20116129.full
AB  - Background Existing analyses of nonpharmaceutical interventions (NPIs) against COVID-19 transmission have focussed on the joint effectiveness of large-scale NPIs. With increasing data, we can move beyond estimating aggregate effects, to understanding the effects of individual interventions. In addition to effectiveness, policy decisions ought to reflect the burden different NPIs put on the population.Methods To our knowledge, this is the largest data-driven study of NPI effectiveness to date. We collected chronological data on 9 NPIs in 41 countries between January and April 2020, using extensive fact-checking to ensure high data quality. We infer NPI effectiveness with a novel semi-mechanistic Bayesian hierarchical model, modelling both confirmed cases and deaths to increase the signal from which NPI effects can be inferred. Finally, we study the burden imposed by different NPIs with an online survey of preferences using the MaxDiff method.Results Six NPIs had a >97.5% posterior probability of being effective: closing schools (mean reduction in R: 58%; 95% credible interval: 50% - 64%), limiting gatherings to 10 people or less (24%; 6% - 39%), closing nonessential businesses (23%; 5% - 38%), closing high-risk businesses (19%; 1% - 34%), testing patients with respiratory symptoms (18%; 8% - 26%), and stay-at-home orders (17%; 5% - 28%). These results show low sensitivity to 12 forms of varying the model and the data. The model makes sensible forecasts for countries and periods not seen during training. We combine the effectiveness and preference results to estimate effectiveness-to-burden ratios.Conclusions Our results suggest a surprisingly large role for schools in COVID-19 transmission, a contribution to the ongoing debate about the relevance of asymptomatic carriers in disease spreading. We identify additional interventions with good effectiveness-burden tradeoffs, namely symptomatic testing, closing high-risk businesses, and limiting gathering size. Closing most nonessential businesses and issuing stay-at-home orders impose a high burden while having a limited additional effect.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funding sources did not influence any aspect of study design, execution, or reporting. The costs for recruiting participants on Amazon Mechanical Turk were covered by a grant from the Berkeley Existential Risk Initiative. Jan Brauner was supported by the EPSRC Centre for Doctoral Training in Autonomous Intelligent Machines and Systems [EP/S024050/1] and by Cancer Research UK. Mrinank Sharma was supported by the EPSRC Centre for Doctoral Training in Autonomous Intelligent Machines and Systems [EP/S024050/1]. Gavin Leech was supported by the UKRI Centre for Doctoral Training in Interactive Artificial Intelligence [EP/S022937/1].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The online surveys on intervention burden were approved by the Medical Sciences Interdivisional Research Ethics Committee at the University of Oxford (Ethics Approval Reference: R69410/RE001)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll NPI data with sources are available in a human-readable format at the first link. All data, including case and death counts, are available in machine-readable format at the second link. https://drive.google.com/file/d/1A1-CDg9KTqwT5myRl--UGNAa5U3AlzRa/view?usp=sharing https://docs.google.com/spreadsheets/d/1k7KV3eDzkaJ47_iXTt_Gjpa3DzZrmLfyHEvBdrcCHRU/edit#gid=1319208660 https://drive.google.com/file/d/1A1-CDg9KTqwT5myRl--UGNAa5U3AlzRa/view?usp=sharing